Acute Kidney Injury Due to Nephrolithiasis in Autosomal Dominant Polycystic Kidney Disease Treated With Tolvaptan: A Case Report

被引:0
|
作者
Shima, Hisato [1 ,2 ]
Nishitani, Masaaki [3 ]
Izaki, Hirofumi [4 ]
Minakuchi, Jun [1 ]
机构
[1] Kawashima Hosp, Kidney Dis, Tokushima, Japan
[2] Kamei Hosp, Nephrol & Hypertens, Tokushima, Japan
[3] Kawashima Hosp, Urol, Tokushima, Japan
[4] Tokushima Prefectural Cent Hosp, Urol, Tokushima, Japan
关键词
tolvaptan; nephrolithiasis; transurethral lithotripsy; acute kidney injury; autosomal dominant polycystic kidney disease; CALCULI;
D O I
10.7759/cureus.62597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 61 -year -old asymptomatic female with autosomal dominant polycystic kidney disease (ADPKD) on tolvaptan therapy was hospitalized for acute kidney injury (AKI). Nephrolithiasis had already been diagnosed; however, the patient had not undergone any interventions. She also presented with hyponatremia possibly caused by overhydration. Because the estimated glomerular filtration rate (eGFR) decline was significantly higher than the predicted rate, we considered a possible case of postrenal AKI and examined computed tomography (CT), which revealed left hydronephrosis with a 9.4 -mm ureteric stone at the level of L3/L4. We restricted fluid intake, which resulted in an increase in sodium levels. She was treated with transurethral lithotripsy (TUL) twice, which successfully improved her kidney function. Although the serum sodium levels increase because of aquaresis in almost all patients treated with tolvaptan, our case was unique in that the patient presented with hyponatremia. We should pay more attention to the periodical follow-up of nephrolithiasis in addition to the increase in total kidney volume and decide the appropriate time to treat nephrolithiasis depending on the case. We should also keep in mind that ADPKD patients have a high frequency of nephrolithiasis and, even if asymptomatic, investigate urinary tract obstruction and hydronephrosis in case of AKI.
引用
收藏
页数:5
相关论文
共 50 条
  • [31] Regional Variance of the Early Use of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease
    Inoue, Reiko
    Nishi, Hiroshi
    Inoue, Daisuke
    Honda, Kenjiro
    Nangaku, Masaomi
    KIDNEY360, 2020, 1 (08): : 2020 - 745
  • [32] Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease
    Akihisa, Taro
    Kataoka, Hiroshi
    Makabe, Shiho
    Manabe, Shun
    Yoshida, Rie
    Ushio, Yusuke
    Sato, Masayo
    Tsuchiya, Ken
    Mochizuki, Toshio
    Nitta, Kosaku
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2022, 26 (06) : 540 - 551
  • [33] Initial decline in eGFR to predict tolvaptan response in autosomal-dominant polycystic kidney disease
    Taro Akihisa
    Hiroshi Kataoka
    Shiho Makabe
    Shun Manabe
    Rie Yoshida
    Yusuke Ushio
    Masayo Sato
    Ken Tsuchiya
    Toshio Mochizuki
    Kosaku Nitta
    Clinical and Experimental Nephrology, 2022, 26 : 540 - 551
  • [34] Long-Term Benefits of Treatment with Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
    Shimoda, Naoko
    Ikeda, Mariko
    Yan, Tomohiro
    Kawasaki, Sayuri
    Hirama, Akio
    Kashiwagi, Tetsuya
    Sakai, Yukinao
    JOURNAL OF NIPPON MEDICAL SCHOOL, 2022, 89 (03) : 287 - 294
  • [35] Autosomal Dominant Polycystic Kidney Disease
    Suarez, Maria Lourdes Gonzalez
    Titan, Silvia
    Dahl, Neera K.
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2024, 31 (06): : 496 - 503
  • [36] Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease
    Shigeo Horie
    Satoru Muto
    Haruna Kawano
    Tadashi Okada
    Yoshiyuki Shibasaki
    Koji Nakajima
    Tatsuki Ibuki
    Clinical and Experimental Nephrology, 2021, 25 : 467 - 478
  • [37] Preservation of kidney function irrelevant of total kidney volume growth rate with tolvaptan treatment in patients with autosomal dominant polycystic kidney disease
    Horie, Shigeo
    Muto, Satoru
    Kawano, Haruna
    Okada, Tadashi
    Shibasaki, Yoshiyuki
    Nakajima, Koji
    Ibuki, Tatsuki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2021, 25 (05) : 467 - 478
  • [38] Autosomal dominant polycystic kidney disease combined with hypertrophic cardiomyopathy A case report
    Shen, Yingjing
    Xu, Chenggang
    MEDICINE, 2017, 96 (46)
  • [39] Amyloidosis in a patient with autosomal dominant polycystic kidney disease and tuberculosis: a case report
    Fuat Sar
    Ismail Taylan
    Cigdem Kutlu
    Muazzez Sezer Caymaz
    Emel Tatli
    Rumeyza Kazancioglu
    International Urology and Nephrology, 2007, 39 : 655 - 659
  • [40] Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
    Kim, Yaerim
    Han, Seungyeup
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (03) : 322 - 331